Maria Papaioannou
A5101853210- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
- Peptidase Inhibition and Analysis
- Immunodeficiency and Autoimmune Disorders
- Chronic Myeloid Leukemia Treatments
- Monoclonal and Polyclonal Antibodies Research
- Platelet Disorders and Treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Blood groups and transfusion
- Histone Deacetylase Inhibitors Research
- Advanced Breast Cancer Therapies
- Immune Cell Function and Interaction
- Hematological disorders and diagnostics
- Blood disorders and treatments
- Complement system in diseases
- HIV Research and Treatment
- T-cell and B-cell Immunology
- Eosinophilic Disorders and Syndromes
- Acute Lymphoblastic Leukemia research
- Cancer Mechanisms and Therapy
AHEPA University Hospital
2016-2025
Aristotle University of Thessaloniki
2016-2025
Centre for Research and Technology Hellas
2018-2023
National and Kapodistrian University of Athens
2023
Metaxa Hospital
2020
Hammersmith Hospital
2013-2017
Imperial College London
2012-2017
Imperial College Healthcare NHS Trust
2017
Hudson Institute
2017
John Wiley & Sons (United States)
2017
Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study characterize course COVID-19 in and identify potential predictors outcome. Of 190 confirmed diagnosed between 28/03/2020 22/05/2020, 151 (79%) presented (need oxygen and/or intensive care admission). Severe was associated advanced...
Abstract Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due age, disease, and treatment-related immunosuppression. We aimed assess risk factors of outcome elucidate the impact CLL-directed treatments on course COVID-19. conducted a retrospective, international study, collectively including 941 patients CLL confirmed Data from beginning pandemic until March 16, 2021, were collected 91 centers. The case fatality rate (CFR),...
Thrombosis is the most common and a life-threatening complication in patients with Paroxysmal Nocturnal Hemoglobinuria. One-third of PNH experience at least one thromboembolic event during course disease, thrombosis being cause death these patients. The mechanism complex continues to be great research interest. Since introduction C5 complement inhibitors treatment PNH, incidence events has decreased substantially. We retrospectively analyzed data concerning thrombotic episodes 41 from 14...
Abstract In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) related disorders (small lymphoma high‐count monoclonal B lymphocytosis) infected by SARS‐CoV‐2, including development post‐COVID condition. Data from 1540 CLL SARS‐CoV‐2 January 2020 to May 2022 were included in analysis assigned four phases based on cases disposition variants emergence. Post‐COVID condition was defined...
Abstract Objectives To evaluate the prognostic impact of hypercalcemia in newly diagnosed patients with symptomatic multiple myeloma ( MM ), especially after incorporation new agents. Methods we analyzed outcomes included database Greek Myeloma Study Group for effect presence (defined as corrected serum calcium ≥11 mg/ dL ) at diagnosis. Results Among 2129 consecutive , 19.5% presented time The was associated anemia, thrombocytopenia, lower estimated glomerular filtration rate eGFR advanced...
Abstract Multiple myeloma is a genetically heterogeneous cancer of the bone marrow plasma cells (PC). Distinct transcriptome profiles are primarily driven by initiating events (MIE) and converge into mutually exclusive overexpression CCND1 CCND2 oncogenes. Here, with reference to their normal counterparts, we find that PC enhanced chromatin accessibility combined paired profiling can classify MIE-defined genetic subgroups. Across within different MM subgroups, ascribe regulation genes...
The aim of the study was to evaluate penetration linezolid into cerebrospinal fluid (CSF) and brain tissue after a single i.v. dose 600 mg. studied in 18 patients undergoing neurosurgical procedure. Linezolid mg given with induction anesthesia. Mean concentrations 2h final dose, serum, cerbrospinal were assayed by HPLC. CSF/serum brain/serum ratios 69.57% 44.66% respectively. Concentrations above MIC(90s )for staphylococci streptococci. obtained indicate good CSF support its use management...
Summary Luspatercept has been approved for the treatment of anaemia in transfusion‐dependent (TD) patients with lower risk (LR) myelodysplastic syndromes (MDS) after erythroid‐stimulated agent (ESA) failure, according to results MEDALIST trial. In this multicentre retrospective study, we report efficacy and safety data luspatercept administered 98 TD LR‐MDS ESA failure. The percentage that stopped due adverse events was comparable reported study. Furthermore, observed 44.3% who had completed...
Biomarkers of bone turnover in serum are suggestive dynamics during treatment multiple myeloma (MM). We evaluated the role daratumumab on remodeling among patients with relapsed/refractory MM prospective, open-label, phase 2 study REBUILD. Daratumumab was administered according to approved indication. A total 33 out 57 enrolled completed 4 months treatment. The median percent change from baseline C-terminal cross-linking telopeptide type 1 collagen (CTX) (primary endpoint) 3.9%, 13 (39.4%)...
The International Federation of Gynecology and Obstetrics (FIGO) nutrition checklist is a tool for everyday antenatal clinical practice, easy to use by most healthcare professionals, aiming initiate conversation regarding gestational weight gain (GWG) identify women who might require further assessment. present cross-sectional study aimed apply the FIGO pregnant attending routine care nutritional risk factors. Pregnant (n = 200) were recruited from outpatient pregnancy clinics two hospitals...
Azacitidine is the mainstay of high-risk myelodysplastic syndromes (MDS) therapy, but molecular predictors response and mechanisms resistance to azacitidine remain largely unidentified. Deregulation signaling via Stat3 Stat5 in acute myeloid leukemia (AML) associated with aggressive disease. Numerous genes involved cell are aberrantly methylated MDS, yet alterations effect treatment on Stat3/5 MDS have not been explored.We assessed longitudinally constitutive ligand-induced phospho-Stat3/5...
Summary Selecting the most appropriate chronic lymphocytic leukaemia (CLL) treatment is challenging. Patient‐reported health‐related quality of life (HRQoL) therefore a critical aspect to consider. This international study by European Organization for Research and Treatment Cancer (EORTC) tested psychometric properties newly developed measure CLL patients: EORTC QLQ‐CLL17 supplement core questionnaire (EORTC QLQ‐C30). Patients with ( n = 341) from 12 countries completed QLQ‐C30, debriefing...
The ontogeny of the natural, public IgM repertoire remains incompletely explored. Here, high-resolution immunogenetic analysis B cells from (unrelated) fetal, child, and adult samples, shows that although fetal liver (FL) bone marrow (FBM) repertoires are equally diversified, FL is main source natural immunity during 2nd trimester. Strikingly, 0.25% all prenatal clonotypes, comprising 18.7% expressed repertoire, shared with postnatal consistent persisting + being a in life. Further, origins...
Expression of CD25 antigen on CD34+ cells is an independent predictor outcome in late-stage MDS patients treated with azacitidine
Hypomethylating agents are widely used in chronic myelomonocytic leukemia (CMML). We analyzed the characteristics of 88 patients with CMML homogeneously treated 5-azacytidine (Hellenic 5-Azacytidine Registry). The overall response rate was 48.9% and median survival (OS) 29.7 months. Out seven most prognostic scoring systems for CMML, Dusseldorf score (DUSS) showed best capability (HR, 2.27; p < .001). Forty-one (48.8%) progressed to acute myeloid (AML) after a time 15.2 months following...
5-azacytidine (5-AZA) improves survival of patients with higher-risk myelodysplastic syndromes (MDSs) and oligoblastic acute myeloid leukemia (AML); however, predictive factors for response outcome have not been consistently studied.This study the Hellenic MDS Study Group included 687 consecutive AML treated 5-AZA.The International Prognostic Scoring System (IPSS) revised version (IPSS-R), Eastern Cooperative Oncology Performance Status (ECOG PS) (0 or 1 versus ⩾2) baseline serum ferritin...